We are live on ! Find out more
AZN icon

AstraZeneca

403 hedge funds and large institutions have $7.09B invested in AstraZeneca in 2014 Q4 according to their latest regulatory filings, with 56 funds opening new positions, 123 increasing their positions, 136 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

87% more call options, than puts

Call options by funds: $958M | Put options by funds: $511M

25% more funds holding in top 10

Funds holding in top 10: 810 (+2)

23% more capital invested

Capital invested by funds: $5.76B → $7.09B (+$1.34B)

14% more first-time investments, than exits

New positions opened: 56 | Existing positions closed: 49

1% more ownership

Funds ownership: 6.39%7.39% (+1%)

0% more funds holding

Funds holding: 401403 (+2)

10% less repeat investments, than reductions

Existing positions increased: 123 | Existing positions reduced: 136

Holders
403
Holders Change
+2
Holders Change %
+0.5%
% of All Funds
10.75%
Holding in Top 10
10
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+25%
% of All Funds
0.27%
New
56
Increased
123
Reduced
136
Closed
49
Calls
$958M
Puts
$511M
Net Calls
+$447M
Net Calls Change
+$28.2M
Name Holding Trade Value Shares
Change
Change in
Stake
RHBC
76
R.H. Bluestein & Co
Michigan
$7.68M +$7.1M +99,195 +992%
HSBC Holdings
77
HSBC Holdings
United Kingdom
$7.48M +$330K +4,611 +5%
MSR
78
Main Street Research
Connecticut
$7.37M +$256K +3,570 +4%
Royal Bank of Canada
79
Royal Bank of Canada
Ontario, Canada
$7.18M +$165K +2,308 +2%
TD Asset Management
80
TD Asset Management
Ontario, Canada
$7.07M +$1.37M +19,087 +23%
HVC
81
Healthcare Value Capital
New Jersey
$7.04M +$1.79M +25,000 +33%
First Trust Advisors
82
First Trust Advisors
Illinois
$6.89M +$1.15M +16,083 +20%
BNP Paribas Financial Markets
83
BNP Paribas Financial Markets
France
$6.54M +$1.03M +14,414 +18%
Citadel Advisors
84
Citadel Advisors
Florida
$6.5M -$4.04M -56,371 -38%
M&T Bank
85
M&T Bank
New York
$6.44M +$333K +4,655 +5%
UOC
86
UBS O'Connor
Illinois
$6.22M
SFM
87
Sphera Funds Management
Israel
$6.1M -$2.39M -33,363 -28%
MPM
88
Meritage Portfolio Management
Kansas
$5.99M +$212K +2,955 +4%
GCC
89
Guardian Capital (Canada)
Ontario, Canada
$5.5M -$136K -1,900 -2%
PL
90
Parkwood LLC
Ohio
$5.47M +$88.9K +1,242 +2%
UBS AM
91
UBS AM
Illinois
$5.38M -$580K -8,106 -10%
ACI
92
AMP Capital Investors
Australia
$5.19M
GG
93
Gofen & Glossberg
Illinois
$5.17M +$91.5K +1,278 +2%
Citigroup
94
Citigroup
New York
$4.99M -$1.77M -24,736 -26%
MC
95
Maplelane Capital
New York
$4.93M +$5.01M +70,000 New
CPIM
96
Columbia Partners Investment Management
Virginia
$4.88M -$156K -2,172 -3%
SLG
97
Stanley-Laman Group
Pennsylvania
$4.86M -$285K -3,978 -5%
NIMC
98
NWQ Investment Management Company
California
$4.68M +$141K +1,965 +3%
Susquehanna International Group
99
Susquehanna International Group
Pennsylvania
$4.64M -$83.6M -1,167,457 -95%
GCAC
100
Guardian Capital Advisors (Canada)
Ontario, Canada
$4.59M -$42.7K -596 -1%

AZN Hedge Fund Activity: Q4 2014 in Review

403 of the 3,749 institutional investors tracked by Wall St. Rank reported a position in AstraZeneca (AZN) for Q4 2014, worth a combined $7.09B — up 23% from $5.76B a quarter earlier.

Buyers outnumbered sellers: 56 funds opened new AZN positions and 49 closed out — a net gain of 7 holders — while 123 added to existing stakes and 136 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $457M. The largest seller was Susquehanna International Group, cutting an estimated $83.6M.

  • 403 institutional investors held AstraZeneca (AZN) as of Q4 2014, up from 401 in Q3 2014.
  • Funds reported $7.09B of AstraZeneca stock for Q4 2014, up 23% quarter-over-quarter.
  • 56 funds opened new AstraZeneca positions in Q4 2014 and 49 closed out, a net change of +7 holders.
  • The largest AstraZeneca buyer in Q4 2014 was Wellington Management Group, an estimated $457M added.
  • The largest AstraZeneca seller in Q4 2014 was Susquehanna International Group, an estimated $83.6M sold.

Based on aggregated 13F filings for Q4 2014.